Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the terms of this agreement Knight will be responsible for obtaining regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina.